| 19-Nortestosterone |
| 434-22-0 |
| 19-Norandrostenolone |
| Norandrostenolone |
| Nortestosterone |
| Menidrabol |
| 17beta-Hydroxy-4-estren-3-one |
| 4-Estren-17beta-ol-3-one |
| Nortestosteronum |
| Nandrolon |
| Nortestonate |
| Nandrolona |
| Nandrolonum |
| Oestrenolon |
| Norandrostenolon |
| 17beta-Hydroxy-19-nor-4-androsten-3-one |
| 17beta-hydroxyestr-4-en-3-one |
| (17beta)-17-hydroxyestr-4-en-3-one |
| 17-beta-Hydroestr-4-en-3-one |
| Nandrolone cIII |
| (17-beta)-17-Hydroxyestr-4-en-3-one |
| Nandrolone (INN) |
| Nandrolone [INN] |
| CHEMBL757 |
| 6PG9VR430D |
| CHEBI:7466 |
| (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one |
| DTXSID7023350 |
| NSC 3351 |
| NSC-3351 |
| NCGC00159416-02 |
| U 2410 |
| (+)-19-Nortestosterone |
| Nandrolonum [INN-Latin] |
| Nandrolona [INN-Spanish] |
| DTXCID403350 |
| decadura |
| decadura (TN) |
| CAS-434-22-0 |
| SMR000058610 |
| HSDB 3368 |
| Nandrolone [INN:BAN] |
| EINECS 207-101-0 |
| Estr-4-en-3-one, 17-hydroxy-, (17beta)- |
| Estr-4-en-3-one, 17beta-hydroxy- |
| 4-Estren-17.beta.-ol-3-one |
| UNII-6PG9VR430D |
| Nandrolone Base |
| Nandrolone, beta |
| Estr-4-en-3-one, 17-hydroxy-, (17b)- |
| Nandrolone, alpha |
| NCGC00164479-01 |
| 19-nor-testosterone |
| BIOBOL |
| Estr-4-en-3-one, 17-beta-hydroxy- |
| 17.beta.-Nandrolone |
| NANDROLONE [MI] |
| Nandrolone Decanoic acid |
| Estr-4-en-3-one, 17-hydroxy-, (17.beta.)- |
| enta[a]phenanthren-3-one |
| NANDROLONE [HSDB] |
| 17.beta.-Nortestosterone |
| NANDROLONE [VANDF] |
| EC 207-101-0 |
| NANDROLONE [MART.] |
| Estr-4-en-3-one, 17-hydroxy-, (17-beta)- |
| NANDROLONE [WHO-DD] |
| SCHEMBL20140 |
| MLS001423989 |
| MLS002222325 |
| 17-Hydroxyestr-4-en-3-one |
| Nandrolone(19-nortestosterone) |
| GTPL6949 |
| Nandrolone, 1mg/ml in Methanol |
| Deca-Durabolin (decanoate ester) |
| NANDROLONE CIII [USP-RS] |
| Durabolin (phenylpropionate ester) |
| HMS2051I04 |
| HMS2098E05 |
| HMS2272P06 |
| HMS3715E05 |
| Tox21_113167 |
| Tox21_113199 |
| Tox21_201212 |
| BDBM50080092 |
| LMST02010044 |
| AKOS015894933 |
| Nandrolone 1.0 mg/ml in Acetonitrile |
| Tox21_113167_1 |
| CCG-100835 |
| CS-1416 |
| DB13169 |
| GS-6819 |
| NC00085 |
| 4-ESTREN-3-ONE-17.BETA.-OL |
| NCGC00159416-03 |
| NCGC00159416-04 |
| NCGC00258764-01 |
| (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one |
| AC-15207 |
| AC-30575 |
| CPD000058610 |
| HY-17432 |
| 19-Nortestosterone, >=99.0% (HPLC) |
| C07254 |
| D08250 |
| Nandrolone, VETRANAL(TM), analytical standard |
| Q421709 |
| SR-01000781257 |
| SR-01000781257-3 |
| W-106227 |
| NANDROLONE DECANOATE IMPURITY D [EP IMPURITY] |
| Nandrolone, British Pharmacopoeia (BP) Reference Standard |
| Nandrolone, United States Pharmacopeia (USP) Reference Standard |
| (1S,2R,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
| (8~{R},9~{S},10~{R},13~{S},14~{S},17~{S})-13-methyl-17-oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1~{H}-cyclop |
| (8~{r},9~{s},10~{r},13~{s},14~{s},17~{s})-13-Methyl-17-Oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-Dodecahydro-1~{h}-Cyclopenta[a]phenanthren-3-One |
| (8R,10R,13S,17S)-17-Hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one |
| 6VW |
|
There are more than 10 synonyms. If you wish to see them all click here.
|